Profile data is unavailable for this security.
About the company
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company also focuses on artificial intelligence (AI) and digital pathology solutions for biopharmaceutical companies and pathology laboratories. It has implemented AI, digital and automation technologies across several laboratory and business functions.
- Revenue in USD (TTM)9.54bn
- Net income in USD838.00m
- Incorporated1996
- Employees40.00k
- LocationQuest Diagnostics Inc500 Plaza DriveSECAUCUS 07094United StatesUSA
- Phone+1 (973) 520-2700
- Fax+1 (302) 655-5049
- Websitehttps://www.questdiagnostics.com/
Mergers & acquisitions
Acquired company | DGX:NYQ since announced | Transaction value |
---|---|---|
University Hospitals Health System-Outreach Laboratory Services Business | 7.59% | -- |
Lifelabs Inc | 18.83% | 987.13m |
Allina Health Systems Inc-Select Laboratory Assets | 17.40% | -- |
PathAI Inc-Select Assets | 17.51% | -- |
Lenco Diagnostic Laboratories Inc | 26.43% | 111.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Encompass Health Corp | 5.22bn | 431.20m | 9.97bn | 22.36k | 23.41 | 5.09 | 11.66 | 1.91 | 4.23 | 4.11 | 51.10 | 19.45 | 0.8396 | -- | 9.38 | 233,270.70 | 9.07 | 6.37 | 11.87 | 7.94 | 95.49 | 95.58 | 10.80 | 9.16 | -- | 6.14 | 0.486 | 30.78 | 10.41 | 2.34 | 41.31 | 4.49 | 16.60 | -10.42 |
Universal Health Services, Inc. | 15.42bn | 1.03bn | 13.04bn | 73.35k | 13.14 | 1.97 | 8.01 | 0.846 | 15.03 | 15.03 | 225.85 | 100.14 | 1.09 | -- | 6.93 | 210,194.40 | 7.41 | 6.44 | 8.68 | 7.63 | -- | -- | 6.78 | 6.55 | 1.28 | 7.70 | 0.4105 | 6.06 | 6.59 | 5.80 | 6.32 | -1.47 | 1.17 | 14.87 |
Davita Inc | 12.67bn | 827.68m | 13.23bn | 70.00k | 17.40 | 34.48 | 7.05 | 1.04 | 9.28 | 9.28 | 141.50 | 4.68 | 0.7357 | 71.34 | 5.90 | 180,951.60 | 6.58 | 5.62 | 8.88 | 7.45 | 32.80 | 30.70 | 8.94 | 8.33 | 1.33 | 4.77 | 0.8115 | -- | 4.57 | 1.26 | 26.44 | 2.33 | -10.47 | -- |
Tenet Healthcare Corp | 20.97bn | 3.13bn | 14.44bn | 78.14k | 4.86 | 3.77 | 3.02 | 0.6885 | 31.26 | 31.26 | 209.81 | 40.32 | 0.7364 | 9.49 | 7.15 | 268,376.30 | 13.86 | 3.61 | 20.23 | 5.09 | 82.61 | 82.97 | 18.83 | 4.95 | 1.52 | 5.37 | 0.6145 | 0.00 | 7.17 | 2.33 | 49.02 | 41.42 | 4.01 | -- |
Molina Healthcare Inc | 39.20bn | 1.14bn | 16.85bn | 18.00k | 14.95 | 3.52 | 12.72 | 0.4299 | 19.70 | 19.70 | 674.97 | 83.68 | 2.56 | -- | 13.71 | 2,177,722.00 | 7.47 | 7.62 | 16.58 | 16.80 | 16.12 | 15.99 | 2.92 | 3.04 | -- | 14.83 | 0.3465 | 0.00 | 6.56 | 12.52 | 37.75 | 9.06 | 22.87 | -- |
Quest Diagnostics Inc | 9.54bn | 838.00m | 18.01bn | 40.00k | 21.66 | 2.65 | 13.49 | 1.89 | 7.45 | 7.45 | 84.79 | 60.79 | 0.645 | 34.77 | 7.18 | 238,475.00 | 5.87 | 9.28 | 6.77 | 10.81 | 32.94 | 36.64 | 9.10 | 12.97 | 1.17 | 8.87 | 0.4746 | 25.07 | -6.38 | 4.20 | -9.77 | 3.40 | 1.27 | 7.43 |
Labcorp Holdings Inc | 12.71bn | 435.50m | 19.89bn | 67.00k | 46.09 | 2.44 | 18.84 | 1.56 | 5.16 | 5.16 | 150.40 | 97.61 | 0.7162 | 19.41 | 5.93 | 189,743.30 | 2.46 | 6.27 | 3.00 | 7.37 | 27.92 | 32.33 | 3.44 | 9.51 | 1.30 | 5.59 | 0.455 | -- | 2.51 | 1.42 | -62.16 | -16.40 | 3.62 | -- |
Natera Inc | 1.53bn | -214.69m | 20.76bn | 3.28k | -- | 23.72 | -- | 13.55 | -1.77 | -1.77 | 12.59 | 7.08 | 1.01 | 14.29 | 5.45 | 466,774.80 | -14.14 | -36.17 | -17.55 | -46.60 | 57.66 | 45.88 | -14.01 | -56.15 | 4.23 | -- | 0.2947 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Sep 2024 | 13.46m | 12.06% |
BlackRock Fund Advisorsas of 30 Sep 2024 | 6.43m | 5.76% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 5.26m | 4.72% |
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 3.69m | 3.31% |
Victory Capital Management, Inc. (Investment Management)as of 30 Sep 2024 | 3.46m | 3.10% |
Geode Capital Management LLCas of 30 Sep 2024 | 2.62m | 2.34% |
Davis Selected Advisers LPas of 30 Sep 2024 | 2.40m | 2.15% |
American Century Investment Management, Inc.as of 30 Sep 2024 | 2.29m | 2.05% |
Grantham, Mayo, Van Otterloo & Co. LLCas of 30 Sep 2024 | 2.24m | 2.01% |
Wellington Management Co. LLPas of 30 Sep 2024 | 1.98m | 1.77% |